Skip to main content

Advertisement

Table 3 Comparison of BAE and non-BAE subjects with hemoptysis

From: Hemoptysis requiring bronchial artery embolization in patients with nontuberculous mycobacterial lung disease

  Medical (n = 45) BAE (n = 33) P-value
Male sex 12 (26.7) 15 (45.5) 0.098
Age, years, at diagnosis 59.5 ± 11.7 60.0 ± 12.1 0.855
BMI, kg/m2 20.5 ± 2.6 19.8 ± 2.9 0.274
Diabetes mellitus 2 (4.4) 4 (12.1) 0.392
Hypertension 8 (17.8) 7 (21.2) 0.704
Performed bronchoscopy 28 (62.2) 24 (72.7) 0.466
Type of chest CT
 Nodular bronchiectatic 38 (84.4) 28 (84.8) 0.961
 Fibrocavitary 7 (15.6) 5 (15.2)  
> 3 lobe distribution of chest CT 8 (17.8) 12 (36.4) 0.073
Antiplatelet/anticoagulation therapy 5 (11.1) 5 (15.2) 0.735
Liver disease 4 (8.9) 5 (15.2) 0.726
History of pulmonary tuberculosis 15 (33.3) 16 (48.5) 0.242
Charlson Comorbidity Index score 1.04 ± 1.1 1.6 ± 2.0 0.119
2 NTM pathogens identified 4 (8.9) 1 (3.0) 0.389
Complication after BAE   0  
Repeat BAE due to rebleeding   8 (24.2)  
Duration between first BAE and rebleedinga   10 (7.5–53.5)a  
Number of BAE trials
 1   25 (75.8)  
 2 5 (15.2)
 5 2 (6.1)
 8 1 (3.0)
  1. Results are presented as n (%) or mean ± standard deviation, unless otherwise indicated
  2. BAE bronchial artery embolization, BMI body mass index, CT computed tomography, NTM nontuberculous mycobacteria, M. Mycobacterium
  3. athis value is presented as median (interquartile range) because of the small number of subjects